Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis

44Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

Abstract

Cancer sera contain antibodies that react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs), and therefore these autoantibodies can be considered as reporters from the immune system, to identify authentic TAAs involved in the malignant transformation. Once a TAA is identified, different approaches would be used to comprehensively characterize and validate the identified TAA/anti-TAA systems that are potential biomarkers in cancer immunodiagnosis. In this manner, several novel TAAs such as p62 and p90 have been identified in our previous studies. p62, a member of IGF-II mRNA binding proteins (IMPs), is an oncofetal protein absent in adult tissues, the presence of anti-p62 autoantibodies relates to abnormal expression of p62 in tumor cells. p90 was recently characterized as an inhibitor of the tumor suppressor PP2A (protein phosphatase 2A), and an autoantibody to p90 appears in high frequency in prostate cancer. The present review will focus on the recent advances in studies mainly associated with these two novel TAAs as biomarkers in cancer immunodiagnosis. © 2010 Elsevier B.V.

Cite

CITATION STYLE

APA

Liu, W., Peng, B., Lu, Y., Xu, W., Qian, W., & Zhang, J. Y. (2011, April). Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2010.12.002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free